![](https://danskbiotek.dk/wp-content/uploads/2020/04/ymabs-300x79.jpg)
Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel 04 December 2020
Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) (the “Company” or “Y-mAbs”) a commercial-stage biopharmaceutical... Read more